Abcam

3D Cell Cultures Technologies Report 2024, Featuring Profiles of Leading Market Participants Including Abcam, Agilent Technologies, Corning, Merck, Beckman Coulter and Synvivo - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Other Science, Research, Pharmaceutical, Science, Agilent Technologies, Collagen, Cancer, Merck, Regenerative medicine, 2D, Abcam, Drug resistance, Gel, Liver disease, Stem cell, 3D, Growth, Drug discovery, Metastasis, Skin, Cell, HCMI, Safety, COVID-19, Cell biology, Patient, Burns, Biology, Software, Corning Inc., 3D printing

3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.

Key Points: 
  • 3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.
  • 3D cell culture models mimic the 3D structure and cell-cell interactions that are found in real tissues, making them more accurate and predictive than traditional 2D cell culture models.
  • There are a variety of 3D cell culture technologies available, including:
    Scaffold-based 3D cell culture: This approach uses a scaffold to provide a 3D support structure for cells to grow on.
  • Bioprinting: This approach uses a 3D printer to deposit cells and biomaterials layer-by-layer to create complex 3D cell culture models.

Global Research Antibodies Market Report 2024, Featuring Profiles of Abcam, Thermo Fisher Scientific, Cell Signaling Technology, Merck, Sino Biological & Bio-Rad - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Infectious Diseases, Health, Science, Research, Antigen, Growth, Bio-Rad Laboratories, ESG, Fever Dream, Therapy, HIV, Thermo Fisher Scientific, Antibody, FDA, Microscopy, IVD, Abcam, Infection, Flow cytometry, Malaria, Merck Group, Vaccine

The global market for research antibodies was valued at approximately $3.5 billion in 2022.

Key Points: 
  • The global market for research antibodies was valued at approximately $3.5 billion in 2022.
  • Among product segments, the primary antibody segment accounted for the highest market share in the global market for research antibodies in 2022.
  • The advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies.
  • This report segments the global market for research antibodies based on type of antibody, clonality, host, major reactivities, application, end user and region.

Mesa Laboratories Appoints Mark Capone to its Board of Directors

Retrieved on: 
Monday, January 8, 2024
Massachusetts Institute of Technology, Danaher Corporation, Medicine, Vulnerable, Audit committee, Abcam, Mesa, Acquisition, Melanoma, Pennsylvania State University, Chemical engineering, Cancer, Genetics, Eli Lilly and Company, Myriad Genetics, Compensated emancipation, MLAB, Management

LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.

Key Points: 
  • LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.
  • Dr. John Sullivan, Ph.D., Chairman of the Board of Directors, stated: “We are pleased to welcome Mark to Mesa’s Board.
  • Mark is an accomplished life sciences executive with significant leadership and acquisitions experience spanning biopharmaceuticals, life science tools, and clinical genomics.
  • “I am honored to be joining the Board of Mesa – a high growth life sciences tools organization built around a vision to Protect the Vulnerable,” said Mark Capone.

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

Retrieved on: 
Monday, December 4, 2023
Science, Public Policy, Government, Other Science, Biotechnology, Research, Pharmaceutical, Health, Courts, Registrar of Companies (India), DHR, Acquisition, NYSE, Transaction, Court order, Part, Eastern Time Zone, Scheme, Danaher Corporation, Registrar, Court, Companies Act 2006, Cryptocurrency, Abcam

The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).

Key Points: 
  • The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).
  • Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.
  • The last day of trading in Abcam ADSs on Nasdaq is expected to be December 5, 2023, with trading in Abcam ADSs on Nasdaq being suspended by 8.00 a.m. (Eastern Time) on December 6, 2023.
  • Capitalized terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Scheme Circular.

Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

Retrieved on: 
Friday, November 17, 2023
Professional Services, Health, Finance, Research, Science, Biotechnology, DHR, Acquisition, NYSE, Transaction, Business, Scheme, Eastern Time Zone, Danaher Corporation, High court, Court, Cryptocurrency, Abcam

The Court Hearing at which the Court will be asked to sanction the Scheme has been scheduled to be held on December 4, 2023.

Key Points: 
  • The Court Hearing at which the Court will be asked to sanction the Scheme has been scheduled to be held on December 4, 2023.
  • An updated expected timetable of principal events is set out below.
  • Capitalized terms in this announcement, unless otherwise defined, have the same meanings as set out in the Scheme Circular.
  • by 8.00 a.m. (Eastern Time) on December 6, 2023
    as soon as practicable after the Effective Time, and in any event not later than five Business Days after the Effective Time

Metabolism Assays Research Report 2023: Market Analysis by Instruments, Assays Kits, Colorimetry, Fluorimetry, Spectrometry, Diagnostics, Research - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 16, 2023
Biotechnology, Pharmaceutical, Health, Agilent Technologies, Abcam, Investment, Hospital, USD, Compound annual growth rate, Diabetes, Drug discovery, Diagnosis, Growth, Region, Colorimetry, ChromeOS, Merck Group, Thermo Fisher Scientific, Research report, Medical device, Fine chemical, Obesity, Spectrometry, Research

The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%

Key Points: 
  • The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%
    This research report categorizes the Metabolism Assays Market by product, technology, application, end-user, and region.
  • Nevertheless, concerns related to the high cost of metabolism assays act as a hindrance to market growth.
  • Moreover, the region benefits from a growing population afflicted with target diseases, further supporting the expansion of the metabolism assays market.
  • Additionally, the report covers aspects such as new product and service launches, mergers and acquisitions, and recent developments within the metabolism assays market.

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

Retrieved on: 
Thursday, November 9, 2023
Technology, Biotechnology, Health, Neurology, Stem Cells, Research, Software, Infectious Diseases, General Health, Internet, Genetics, Health Technology, Science, Data Management, NanoString Technologies, Society, Neuro, Abcam, SMI, University, Neuroinflammation, Max Planck, Poster, HIV disease progression rates, RNA, Medical imaging, Vaccine

NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.

Key Points: 
  • NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.
  • The presentation will be delivered by Caleb Stokes, M.D., Ph.D. of the University of Washington at NanoSymposium (NANO22.08) on Sunday, Nov. 12, from 2:45-3:00 PM EST.
  • “With this unprecedented capability, researchers will gain critical insights into single cell signaling for healthy and diseased brain tissue.
  • The opportunity for future patient benefit is enormous,” said Brad Gray, President and CEO of NanoString.

Danaher Completes Acquisition of Abcam

Retrieved on: 
Wednesday, December 6, 2023
Scheme, Acquisition, Court, Cryptocurrency, Security (finance), Abcam

The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023.

Key Points: 
  • The acquisition of Abcam for $24.00 per share in cash was implemented by way of a Court-sanctioned scheme of arrangement under the UK Companies Act 2006 (the "Scheme") and the Scheme became effective in accordance with its terms on December 6, 2023.
  • As a result, Abcam has become an indirect wholly owned subsidiary of Danaher.
  • Trading of Abcam ADSs on Nasdaq has been suspended.
  • The consideration due to former Abcam shareholders will be settled pursuant to the terms of the Scheme and the consideration due to former Abcam ADS holders will be settled by the Depositary pursuant to the terms of the Deposit Agreement, in each case as further described in the shareholder circular relating to the Scheme, which was published by Abcam on October 5, 2023.

Global Metabolism Assays Markets 2023-2028 with Merck, Thermo Fisher, Abcam, and Agilent Technologies Dominating

Retrieved on: 
Wednesday, November 15, 2023
Agilent Technologies, Abcam, Investment, Hospital, USD, Compound annual growth rate, Diabetes, Drug discovery, Diagnosis, Growth, Region, Colorimetry, ChromeOS, Merck Group, Thermo Fisher Scientific, Research report, Medical device, Fine chemical, Obesity, Research

The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%

Key Points: 
  • The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8%
    This research report categorizes the Metabolism Assays Market by product, technology, application, end-user, and region.
  • Nevertheless, concerns related to the high cost of metabolism assays act as a hindrance to market growth.
  • Moreover, the region benefits from a growing population afflicted with target diseases, further supporting the expansion of the metabolism assays market.
  • (UK), and Agilent Technologies Inc. (US), among others, in the metabolism assays market.

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign

Retrieved on: 
Wednesday, November 1, 2023
Danaher, Sale, NYSE, Human, Acquisition, Shadow board, DHR, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Management, Abcam

“After extensive feedback from the majority of Abcam’s shareholders, I have today decided to suspend my “Vote AGAINST” campaign.

Key Points: 
  • “After extensive feedback from the majority of Abcam’s shareholders, I have today decided to suspend my “Vote AGAINST” campaign.
  • It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stand in the way of the deal.
  • Although this outcome is not what I envisioned, I accept the result and wish Abcam and Danaher all the best for their future.
  • A special thanks also goes to my team of advisors who, acting with integrity and honesty, ensured every shareholder's voice was heard.